Mok, T. S. K., Yu, H. A., Lim, S. M., Okamoto, I., Pérol, M., Novello, S., Dooms, C. A., Sun, J., Kao, S. C., Jänne, P. A., Reck, M., Steuer, C. E., Nishio, M., Wu, Y. L. C., Li, X., Fougeray, R., Kudchadkar, R., Wu, J., Esker, S., Passaro, A. (2025). Patritumab deruxtecan (HER3-DXd) in resistant
            <i>EGFR</i>
            -mutated (
            <i>EGFR</i>
            m) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.8506